Capricor Therapeutics (CAPR) Current Deferred Revenue (2014 - 2026)

Capricor Therapeutics' Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $12.0 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue changed 0.0% year-over-year to $12.0 million; the TTM figure through Mar 2026 stood at $12.0 million (changed 0.0% YoY), while the FY2025 annual figure was $12.0 million, changed N/A from the prior year.
• Current Deferred Revenue was $12.0 million for Q1 2026 at Capricor Therapeutics, roughly flat from $12.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $40.0 million in Q1 2022 to a low of $12.0 million in Q1 2025.
• Historically, Current Deferred Revenue has averaged $19.4 million across 5 years, with a median of $16.9 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue surged 86.16% in 2023, then plunged 48.32% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $18.0 million in 2022, then jumped by 34.98% to $24.3 million in 2023, then sank by 45.9% to $13.1 million in 2024, then declined by 8.61% to $12.0 million in 2025, then changed by 0.0% to $12.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $12.0 million (Q1 2026), $12.0 million (Q4 2025), and $12.0 million (Q3 2025), per Business Quant data.